Mizolen (Mizolastine)

Mizolastine selectively blocks peripheral H1 histamine receptors, preventing histamine from triggering the cascade that causes vasodilation, increased vascular permeability, and nerve irritation. By inhibiting this pathway, the drug diminishes both early and late phase allergic responses, leading to reduced itching, swelling and other allergy symptoms.

The appropriate dose of Mizolen is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of symptoms and any co‑existing medical conditions. Dosage recommendations are individualized, and patients should follow the prescriber’s instructions without altering the regimen.

Safety data for mizolastine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus, and breastfeeding mothers should consult their physician before use.

To request Mizolen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mizolastine is a second‑generation H1 antagonist that offers effective allergy relief with a lower propensity for central nervous system effects compared with many first‑generation antihistamines. Its selectivity for peripheral H1 receptors often results in reduced drowsiness, though individual responses may vary.

Mizolen tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain potency throughout its shelf life.

Mizolen is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s guidance.

Although uncommon, serious adverse reactions can include angioedema (swelling of the face, lips or throat), severe skin rashes such as Stevens‑Johnson syndrome, and anaphylactic reactions. Patients experiencing any of these symptoms should seek immediate medical attention.

Mizolen is contraindicated in individuals with known hypersensitivity to mizolastine or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic or renal impairment, and it should be avoided in those taking medications that have a major interaction risk unless closely monitored.